Bio-Rad Laboratories (BIO) Liabilities and Shareholders Equity (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $9.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 1931.12% year-over-year to $9.8 billion; the TTM figure through Mar 2026 stood at $30.1 billion (up 196.28% YoY), while the FY2025 annual figure was $10.6 billion, up 12.95% from the prior year.
• Liabilities and Shareholders Equity fell to $9.8 billion in Q1 2026 per BIO's latest filing, from $10.6 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $14.4 billion in Q1 2022 and bottomed at $600000.0 in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $7.4 billion across 5 years, with a median of $9.7 billion in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 99.71% — and 2023, when it jumped 82083.33%.
• Bio-Rad Laboratories' Liabilities and Shareholders Equity stood at $600000.0 in 2022, then surged by 82083.33% to $493.1 million in 2023, then jumped by 1799.03% to $9.4 billion in 2024, then climbed by 12.95% to $10.6 billion in 2025, then fell by 7.44% to $9.8 billion in 2026.
• Business Quant data shows BIO's Liabilities and Shareholders Equity at $9.8 billion in Q1 2026, $10.6 billion in Q4 2025, and $9.7 billion in Q3 2025.